semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Acute Back Pain All subjects underwent a detailed history and systemic physical examination including neurologic and musculoskeletal evaluations. To rule out any confounding etiologies, basic diagnostic laboratory tests including complete blood count and acute phase reactants (erythrocyte sedimentation rate and C-reactive protein) were performed. The patients diagnosed as having acute non-specific low back pain according to history and physical examinations were invited to participate and will be informed about the purpose and course of the study. Main A primary complaint of pain in the area between the 12th rib and buttock crease without leg pain Female or male, 20 years of age Low back pain of less than six weeks' duration; and at least moderate pain intensity (NRS≧4)  Main Known or suspected serious spinal pathology and spinal implants Lumbar spinal surgery within the preceding six months Serious comorbidities preventing prescription of paracetamol Alternative treatment for low back pain in previous two weeks Chronic neurological lesion Chronic musculoskeletal lesion Active cancer Pregnancy Use of pain medication (except paracetamol) within 3 days
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Infertility, Female   Known systemic diseases, e.g. Autoimmune disease, scleroderma, malignant disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Maternal Health Child Health Vaccination Family Planning Services Currently married women of reproductive age not currently pregnant and did not have delivery within last 6 months Mothers of children aged 12-23 months for assessing children's vaccination coverage, and Mothers of children aged 0-11 months for assessing ANC, delivery care, PNC and vaccination coverage The service providers
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Ovarian Cysts Chronic Renal Insufficiency woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy patient with chronic renal insufficiency undergoing peritoneal dialysis informed consent obtained  pregnancy or breast-feeding non affiliation to health care insurance treatment with corticosteroids over 15 mg/day treatment with rituximab
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 60.0-120.0,  Osteo Arthritis Knee Criteria:• Patients undergoing primary TKR at the RD+E Hospital Patients must have completed a consent form for the study Patients must be prepared to comply with the pre and post-operative investigations, rehabilitation, attendance schedule and questionnaire schedule of the study Patient in whom any varus deformity present is <20° The diagnosis is of tricompartmental osteoarthritis of the knee Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD) BMI<40 Aged =/> 60 years at time of surgery  • Refusal to consent to the study If the knee for surgery has a fixed flexion deformity ≥15° this will be assessed by a lateral "heel-hang" x-ray of the knee for surgery If the knee for surgery has a varus deformity ≥20° If the knee for surgery has a valgus deformity i.e. hip/knee/ankle alignment angle <0° Pre-op Oxford Knee Score <8 Pre-op knee flexion ability <90° If the natural posterior tibial slope measured is in excess of 10° Any patient whose post-operative recovery or ability to comply with the post-operative rehabilitation and assessment schedules is compromised by known existing other medical conditions Pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Hyperphosphatemia Children aged from 6 to 18 years With end stage renal disease on regular hemodialysis With hyperphosphatemia (serum phosphorus > 4.5mg/dL ) Both genders will be included Given informed concent  Children < 6 years Severe Gastrointestinal disorder Known hypersensitivity to phosphate binders Inability or rejection to give informed consent Normal serum phosphate level
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-79.0,  Secondary Hyperparathyroidism Average serum PTH>240 pg/mL during 2 weeks at the screening Serum corrected Ca≧8.4 mg/dL at the screening Stable chronic kidney disease patients who undergo hemodialysis or hemodialysis filtration  Primary hyperparathyroidism Severe liver disease Severe Cardiac disease History or family history of Long QT syndrome Malignant tumor Uncontrolled diabetes mellitus Uncontrolled hypertension A history of severe drug allergy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Vitamin D2 Supplementation in Vitamin D Insufficiency Adult age ≥ 15 years 2. BMI 18 kg/m2 3. Serum 25(OH)D < 30ng/ml  Hypercalcemia, nephrolithiasis, or fractures 2. Hepatic disease 3. Kidney disease 4. Granulomatous disease 5. Currently supplemented with vitamin D
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Vitamin D Deficiency Subjects with vitamin D deficiency  Subjects who experienced a hypersensitivity to the cholecalciferol Subjects with Hypercalcemia Subjects with Hypercalciuria Subjects with renal impairment Subjects with calcium stone Subjects diagnosed with sarcoidosis or pseudo-hypoparathyroidism Subjects who are to take vitamin D supplements during the study period
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Coronary Syndrome (ACS) Non-valvular Atrial Fibrillation (NVAF) ≥ 18 years ACS patients concomitant non-valvular AF (paroxysmal, persistent and permanent) underwent PCI and new-generation DES implantation CHA2DS2-VASc score ≥ 2 Acceptable risk of bleeding at the discretion of the researchers (e.g. HAS-BLED score ≤ 2) Consent to participate in the trial  DES implanted in the left main coronary artery Cardiogenic shock or Killip III-IV STEMI patients with malignant arrhythmias or underwent electrodefibrillation or CPR or with cardiac mechanical complications (heart rupture, ventricular septal perforation, nipple muscle fracture, etc.) History of gastrointestinal or intracranial hemorrhage; active bleeding, trauma or major surgery within one month; suspected or diagnosed aortic dissection Ischemic stroke with limb dysfunction or dysphasia Known allergy or intolerance to the study medications: warfarin, clopidogrel, aspirin, dabigatran, ticagrelor and heparin Participating in other ongoing trials Planned surgery in 12 months requiring to withdraw the antiplatelet agents Planned RFCA or left atrial appendage occlusion in the next 12m Abnormal liver or kidney function (ALT ≥ 3 ULN; estimated CrCl < 30 ml/min calculated by Cockcroft-Gault equation); diagnosed liver cirrhosis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypertension (answer must be yes to all to enter trial; check yes or no) º ≥ 18 years of age º Stage 1 Prehypertension (office BP 120-129/80-84 mmHg and normal ABPM <130/80)  (answer must be no to all to enter trial) º Diabetes mellitus or other systemic disease º Cardiopulmonary disease º Treatment with antihypertensive medications º eGFR< 60 ml/min/1.73m2 º Pregnancy º Hypersensitivity to nitroprusside or phenylephrine º Psychiatric illness º H/o substance abuse or current smoker º H/o malignancy º Serum Phos <2.4 mg/dL or >4.5 mg/dL
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  FM and PTSD Only Veteran and civilian participants in whom a physical examination and medical history indicate that the participant meets current diagnostic for FM, as specified by the American College of Rheumatology, will be eligible for the study Eligible participants who agree to a blood draw for measurement of biomarkers, must be free of medications and other substances (e.g., illicit drugs and alcohol) that may alter results for 2-6 weeks depending on the medication and frequency of use (which must be cleared by MD consultants) If on pain medications with short half-lives, participants must be off of them for 5 half-lives before testing, generally about 24 hours Any FM participant with an ICD-10 chronic pain diagnosis of a musculoskeletal etiology, will also be eligible for in the study as many individuals with FM also have such conditions Any participant with a confirmed psychiatric diagnosis of PTSD will be included in the study. Individuals in the PTSD group must meet diagnostic for current chronic PTSD (>3 months) as assessed by the CAPS-5, 1-Month Diagnostic Version  Participants will be excluded from participation in the study if they have a life threatening or acute physical illness (e.g., cancer) Current schizophreniform illnesses (except for Psychosis NOS due to PTSD-related sensory hallucinations) Untreated bipolar disorder Or active suicidal or homicidal ideation requiring clinical intervention Individuals with current or past alcohol and/or substance dependence (less than three months from date of screening assessment) will be excluded Individuals seeking interventional pain treatment, such as surgical interventions or other pain clinic interventions, will also be excluded unless they agree to participate in the biomarker procedure prior to the start of their pain intervention Finally, participants who have a neuropathic origin to their pain will be excluded
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Pain, Chronic Opioid Use Age 18-65 2. With and without history of chronic muscle-skeletal pain * 3. Scheduled to undergo elective abdominal surgery requiring overnight hospital admission 4. Opioid naïve** 5. Willing to comply with study procedures as outlined in the protocol 6. Willing and able to provide informed consent 7. Having an email address and access to a computer or electronic tablet  Current use of opioids (includes ANY use in past 3 months) 2. Cancer diagnosis 3. Patient presenting the following documented conditions: Untreated psychosis Current suicidal ideation Current substance abuse
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Listeria Monocytogenes One pregnant woman with listeria monocytogenes bacteremia in the first trimester
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Acromioclavicular Joint Dislocation First acute acromioclavicular dislocation Rockwood Type III  Previous injury to acromioclavicular Joint Previous surgery of acromioclavicular Joint Known hypersensitivity or allergy to fabric of investigational product Pregnancy Known or suspected non-compliance, drug or alcohol abuse Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Vitamin D Deficiency Participants in the from 2008 to 2014 Participants who were examined for serum 25-hydroxyvitamin D level  Participants without serum 25-hydroxyvitamin D level data
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 14.0-100.0,  Outcome General population  Subjects who do not sign informed consent and do not give authorization will be excluded from the study Subjects fed through parenteral feeding
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Malignant Breast Neoplasm Carcinoma, Basal Cell Carcinoma, Squamous Cell Melanoma Skin Neoplasm Head and Neck Neoplasms Subject must be capable of giving informed consent or has an acceptable surrogate capable of giving consent on behalf of the subject. 2. Subject has an eligible tumor that is within 5 mm of the surface (either skin or mucosa) or has had a tumor removed with a tumor bed that is within 5 mm of the surface. 1. Eligible tumors types Intraoral tumors: squamous cell carcinoma (SCC), melanoma Primary cutaneous tumors (including, but not limited to): SCC, basal cell carcinoma (BCC,) melanoma Breast malignancies post surgery Other tumors: any tumor within 5 mm of the surface and with planned radiation therapy  Previous adverse reaction to a charcoal product e.g., a local hypersensitive response from a black tattoo or from ingestion of activated charcoal 2. Previous adverse reaction to the suspending agent 3. Subject has a pacemaker that is not known to be MRI compatible 4. Subject has a non-removable implant or device with metal that is not known to be MRI compatible 5. Subject is pregnant or has a likelihood for becoming pregnant during the basic study timeframe. Note: There is no known harm to the woman or her fetus from participating; this is precautionary only
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Gout CKD Stage 1-4 SUA Level (>8 mg/dL; 480 µmol/L) outpatient adults withgout and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L) outpatient adults with CKD 1-4 stages and hyperurecemia (SUA level above 8 mg/dL (480 µmol/L)  CKD 5 stage heart failure III-IV NYHA stroke peripheral arterial disease obesity with BMI above 30 kg/m2 hypertension 3 grade insulin-dependent DM any kind of cancer inpatient intensive unit patients
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Metabolic Syndrome To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months  the presence of severe physical disability, psychiatric disorder, malignant tumors, pregnancy, chronic alcohol consumption, gout, heart failure, liver and renal dysfunction
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Adult patients (age ≥18 years) Biologic naïve patients with active RA diagnosed according to the revised 1987 American College of Rheumatology (ACR) (Arnett et al. 1988) or 2010 ACR / European League Against Rheumatism (EULAR) Rheumatoid Arthritis classification (Aletaha et al. 2010) Patients should be receiving a stable dose Methotrexate (MTX) for at least 3 months prior to enrolment, and still have active disease defined as erythrocyte sedimentation rate (ESR) ≥28 mm/h and swollen and tender joints ≥ 6 Absence of tuberculosis demonstrated by negative chest X-ray  Patient <18 years Previous treatment with biologics Patients who meet any of the contraindications to the administration of infliximab Previous or concurrent malignancies
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 10.0-95.0,  Vitamin D Deficiency National Health and Nutrition Examination Survey) 2008-2012 participants  missing value on 25-hydroxyvitamin D levels data on another household member was unavailable the precise family relationship between the subjects was unclear